The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
RAD001 and zoledronic acid in patients with renal cell carcinoma with bone metastases (RAZOR): A randomized phase II trial.
Reuben James Broom
No relevant relationships to disclose
Vicky Hinder
No relevant relationships to disclose
Katrina Sharples
No relevant relationships to disclose
Janie Proctor
No relevant relationships to disclose
Steven Duffey
No relevant relationships to disclose
Stephanie Pollard
No relevant relationships to disclose
Peter C.C. Fong
No relevant relationships to disclose
Garry Forgeson
No relevant relationships to disclose
Anne O'Donnell
No relevant relationships to disclose
Dean Laurence Harris
No relevant relationships to disclose
Sanjeev Deva
No relevant relationships to disclose
Michael B. Jameson
No relevant relationships to disclose
Richard T. North
No relevant relationships to disclose
Andrew Grey
No relevant relationships to disclose
Michael P. N. Findlay
No relevant relationships to disclose